Living With T1D/September 4, 2026/2 min read

Can Type 2 Diabetes Medications Help People with Type 1 Diabetes on Insulin Pumps?

Researchers are exploring whether drugs originally designed for type 2 diabetes might offer benefits—like weight loss and better blood sugar control—when added to automated insulin delivery systems. Early results are promising, but more research is needed.

PubMed indexed literature

Evidence label explains the kind of source behind this article (for example peer-reviewed literature vs community video). It is not medical advice.

living with t1dmental healthtechnologysupport

Key takeaways

Some type 2 diabetes medications, when added to automated insulin delivery systems, may help people with type 1 diabetes lose weight and reduce insulin doses
Early studies suggest these adjunctive treatments can improve time in target blood sugar range without increasing hypoglycemia risk
Longer and larger studies are still needed to confirm safety and effectiveness over time
These medications are being investigated only for people with type 1 diabetes who are overweight or obese

Why Researchers Are Looking at Type 2 Diabetes Drugs for Type 1

Automated insulin delivery (AID) systems—also called artificial pancreas technology—are now recognized as the most effective and safe way to manage type 1 diabetes. But researchers have noticed that many people with type 1 diabetes also struggle with weight gain and cardiovascular risk factors, similar to challenges seen in type 2 diabetes.

This has sparked interest in a new question: could medications already approved for type 2 diabetes help people with type 1 diabetes who use automated insulin pumps? Several classes of drugs are being studied for this purpose, including GLP-1 receptor agonists, combination medications, and SGLT2 inhibitors.

What the Early Studies Show

A recent review of available research found that three types of medications showed potential when added to AID systems in people with type 1 diabetes who are overweight or obese:

Weekly injections of semaglutide and tirzepatide were associated with meaningful weight loss, lower daily insulin requirements, and improved time in target blood sugar range. Importantly, these gains did not come with increased risk of low blood sugar (hypoglycemia) or diabetic ketoacidosis (DKA).

Empagliflozin, an SGLT2 inhibitor, was linked to better time in target range and reduced insulin needs. While mean plasma ketone levels increased, DKA remained rare in the studies reviewed.

Important Limitations and Next Steps

While these early findings are encouraging, researchers emphasize that the current evidence is limited. Most studies were small, and more research involving larger groups of people and longer follow-up periods is essential before drawing firm conclusions about long-term safety and effectiveness.

If you use an automated insulin delivery system and are considering any new medication, discuss the potential benefits and risks with your healthcare team. These medications are not yet standard practice for type 1 diabetes and should only be explored under medical supervision.

Evidence label

Source: Diabetes technology & therapeutics. Evidence type: PubMed indexed literature. Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

Type1Cure is an information and intelligence hub, not a medical advice service. This article summarizes published research and does not provide diagnosis, treatment, or personal medical guidance. Always talk to your own care team before changing anything about your Type 1 diabetes management.

More evidence-labeled coverage across the Type1Cure library.